Charles River Laboratories EBITDA 2010-2024 | CRL

Charles River Laboratories annual and quarterly EBITDA history from 2010 to 2024. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
  • Charles River Laboratories EBITDA for the quarter ending June 30, 2024 was $0.238B, a 2.01% decline year-over-year.
  • Charles River Laboratories EBITDA for the twelve months ending June 30, 2024 was $0.893B, a 6.46% decline year-over-year.
  • Charles River Laboratories 2023 annual EBITDA was $0.931B, a 2.46% decline from 2022.
  • Charles River Laboratories 2022 annual EBITDA was $0.955B, a 11.63% increase from 2021.
  • Charles River Laboratories 2021 annual EBITDA was $0.855B, a 28.12% increase from 2020.
Charles River Laboratories Annual EBITDA
(Millions of US $)
2023 $931
2022 $955
2021 $855
2020 $668
2019 $549
2018 $493
2017 $419
2016 $364
2015 $301
2014 $276
2013 $258
2012 $265
2011 $280
2010 $120
2009 $273
Charles River Laboratories Quarterly EBITDA
(Millions of US $)
2024-06-30 $238
2024-03-31 $211
2023-12-31 $213
2023-09-30 $230
2023-06-30 $243
2023-03-31 $245
2022-12-31 $241
2022-09-30 $226
2022-06-30 $264
2022-03-31 $224
2021-12-31 $240
2021-09-30 $224
2021-06-30 $206
2021-03-31 $185
2020-12-31 $190
2020-09-30 $192
2020-06-30 $134
2020-03-31 $152
2019-12-31 $161
2019-09-30 $145
2019-06-30 $129
2019-03-31 $115
2018-12-31 $144
2018-09-30 $128
2018-06-30 $120
2018-03-31 $101
2017-12-31 $96
2017-09-30 $108
2017-06-30 $113
2017-03-31 $102
2016-12-31 $105
2016-09-30 $93
2016-06-30 $90
2016-03-31 $76
2015-12-31 $76
2015-09-30 $80
2015-06-30 $80
2015-03-31 $66
2014-12-31 $67
2014-09-30 $73
2014-06-30 $76
2014-03-31 $60
2013-12-31 $54
2013-09-30 $68
2013-06-30 $68
2013-03-31 $67
2012-12-31 $60
2012-09-30 $63
2012-06-30 $74
2012-03-31 $68
2011-12-31 $67
2011-09-30 $65
2011-06-30 $80
2011-03-31 $68
2010-12-31 $-32
2010-09-30 $39
2010-06-30 $60
2010-03-31 $54
2009-12-31 $69
2009-09-30 $69
2009-06-30 $74
2009-03-31 $62
Sector Industry Market Cap Revenue
Medical Medical Services $9.742B $4.129B
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
Stock Name Country Market Cap PE Ratio
Elevance Health (ELV) United States $96.890B 12.02
Cencora (COR) United States $46.107B 17.62
DiDi Global (DIDIY) China $23.233B 0.00
ICON (ICLR) Ireland $18.679B 16.64
Revvity (RVTY) United States $15.535B 26.63
Avantor (AVTR) United States $15.498B 23.24
Natera (NTRA) United States $15.385B 0.00
Viatris (VTRS) United States $13.858B 4.22
BioMerieux (BMXMF) France $13.601B 0.00
Solventum (SOLV) United States $12.636B 0.00
CochLear (CHEOY) Australia $12.565B 0.00
Medpace Holdings (MEDP) United States $10.202B 28.74
Sonic Healthcare (SKHHY) Australia $8.273B 0.00
HealthEquity (HQY) United States $7.792B 42.29
Doximity (DOCS) United States $7.787B 49.34
Bausch + Lomb (BLCO) Canada $6.975B 32.47
Life Times (LTH) United States $4.762B 31.52
PACS (PACS) United States $4.502B 0.00
Sotera Health (SHC) United States $4.367B 23.36
Organon (OGN) United States $4.239B 4.28
Surgery Partners (SGRY) United States $3.778B 41.86
BrightSpring Health Services (BTSG) United States $3.070B 65.30
Ardent Health Partners (ARDT) United States $2.577B 0.00
Alignment Healthcare (ALHC) United States $2.546B 0.00
Concentras Parent (CON) United States $2.480B 0.00
Premier (PINC) United States $2.271B 11.34
GoodRx Holdings (GDRX) United States $2.254B 84.86
GeneDx Holdings (WGS) United States $2.057B 0.00
Ryman Healthcare (RYHTY) New Zealand $2.036B 0.00
Teladoc Health (TDOC) United States $1.575B 0.00
AMN Healthcare Services Inc (AMN) United States $1.507B 7.57
Progyny (PGNY) United States $1.425B 25.06
Establishment Labs Holdings (ESTA) $1.338B 0.00
Pediatrix Medical (MD) United States $1.319B 12.91
CareDx (CDNA) United States $1.228B 0.00
Agilon Health (AGL) United States $1.123B 0.00
Embecta (EMBC) United States $0.864B 5.76
InnovAge Holding (INNV) United States $0.822B 0.00
QDM (QDMI) Hong Kong, SAR China $0.790B 20.69
SBC Medicals (SBC) United States $0.722B 0.00
Auna S.A (AUNA) Luxembourg $0.488B 0.00
Sonida Senior Living (SNDA) United States $0.483B 0.00
Enhabit (EHAB) United States $0.382B 33.04
DocGo (DCGO) United States $0.355B 13.35
COMPASS Pathways (CMPS) United Kingdom $0.309B 0.00
Sera Prognostics (SERA) United States $0.255B 0.00
ModivCare (MODV) United States $0.232B 7.37
Beauty Health (SKIN) United States $0.211B 0.00
Biodesix (BDSX) United States $0.195B 0.00
LifeMD (LFMD) United States $0.192B 0.00
Ascend Wellness Holdings (AAWH) United States $0.178B 0.00
MultiPlan (MPLN) United States $0.136B 0.00
Nutex Health (NUTX) United States $0.127B 0.00
So-Young (SY) China $0.092B 22.35
Harvard Apparatus Regenerative Technology (HRGN) United States $0.059B 0.00
Singular Genomics Systems (OMIC) United States $0.057B 0.00
OncoCyte (OCX) United States $0.049B 0.00
NeueHealth (NEUE) United States $0.041B 1.63
Co-Diagnostics (CODX) United States $0.039B 0.00
IceCure Medical (ICCM) Israel $0.036B 0.00
NeuroOne Medical Technologies (NMTC) United States $0.027B 0.00
Pheton Holdings (PTHL) China $0.027B 0.00
Oncology Institute (TOI) United States $0.021B 0.00
SeaStar Medical Holding (ICU) United States $0.012B 0.00
XWELL (XWEL) United States $0.009B 0.00
Intelligent Bio Solutions (INBS) United States $0.007B 0.00
BioNexus Gene Lab (BGLC) $0.007B 0.00
KindlyMD (KDLY) United States $0.005B 0.00
ISpecimen (ISPC) United States $0.004B 0.00
NewGenIvf Group (NIVF) Thailand $0.003B 0.00
Aclarion (ACON) United States $0.002B 0.00
Cano Health (CANOQ) United States $0.001B 0.00